GNAS and pituitary gland adenoma: This result was seemingly supported by preceding reports that pituitary adenomas with the gsp oncogene mutation were shown to experience stronger GH suppression by octreotide and pituitary adenomas with gsp mutation were more likely to be TRH responders [17, 18].